Linked Life Data

20220777

Source:http://linkedlifedata.com/resource/pubmed/id/20220777

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20220777rdf:typepubmed:Citationlld:pubmed
pubmed-article:20220777lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:20220777lifeskim:mentionsumls-concept:C1332717lld:lifeskim
pubmed-article:20220777lifeskim:mentionsumls-concept:C1706438lld:lifeskim
pubmed-article:20220777lifeskim:mentionsumls-concept:C0023434lld:lifeskim
pubmed-article:20220777lifeskim:mentionsumls-concept:C0085358lld:lifeskim
pubmed-article:20220777lifeskim:mentionsumls-concept:C0030956lld:lifeskim
pubmed-article:20220777lifeskim:mentionsumls-concept:C0042196lld:lifeskim
pubmed-article:20220777lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:20220777lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:20220777lifeskim:mentionsumls-concept:C1413244lld:lifeskim
pubmed-article:20220777lifeskim:mentionsumls-concept:C2698600lld:lifeskim
pubmed-article:20220777lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:20220777lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:20220777lifeskim:mentionsumls-concept:C1511636lld:lifeskim
pubmed-article:20220777pubmed:issue4lld:pubmed
pubmed-article:20220777pubmed:dateCreated2010-4-14lld:pubmed
pubmed-article:20220777pubmed:abstractTextThe receptor for hyaluronic acid-mediated motility (RHAMM) is a tumor-associated antigen in chronic lymphocytic leukemia (CLL). CD8(+) T cells primed with the RHAMM-derived epitope R3, which is restricted by human leukocyte antigen (HLA)-A2, effectively lyse RHAMM(+) CLL cells. Therefore, we initiated a phase I clinical trial of R3 peptide vaccination. Six HLA-A2(+) CLL patients were vaccinated four times at biweekly intervals with the R3 peptide (ILSLELMKL; 300 microg per dose) emulsified in incomplete Freund's adjuvant; granulocyte-macrophage colony stimulating factor (100 microg per dose) was administered concomitantly. Detailed immunological analyses were conducted throughout the course of peptide vaccination. No severe adverse events greater than CTC I degrees skin toxicity were observed. Four patients exhibited reduced white blood cell counts during vaccination. In five of six patients, R3-specific CD8(+) T cells were detected with the corresponding peptide/HLA-A2 tetrameric complex; these populations were verified functionally in four of five patients using enzyme-linked immunosorbent spot (ELISpot) assays. In patients with clinical responses, we found increased frequencies of R3-specific CD8(+) T cells that expressed high levels of CD107a and produced both interferon-gamma and granzyme B in response to antigen challenge. Interestingly, vaccination was also associated with the induction of regulatory T cells in four patients. Thus peptide vaccination in six CLL patients was safe and could elicit to some extent specific CD8(+) T-cell responses against the tumor antigen RHAMM.lld:pubmed
pubmed-article:20220777pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20220777pubmed:languageenglld:pubmed
pubmed-article:20220777pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20220777pubmed:citationSubsetIMlld:pubmed
pubmed-article:20220777pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20220777pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20220777pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20220777pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20220777pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20220777pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20220777pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20220777pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20220777pubmed:statusMEDLINElld:pubmed
pubmed-article:20220777pubmed:monthAprlld:pubmed
pubmed-article:20220777pubmed:issn1476-5551lld:pubmed
pubmed-article:20220777pubmed:authorpubmed-author:SchmittMMlld:pubmed
pubmed-article:20220777pubmed:authorpubmed-author:PriceD ADAlld:pubmed
pubmed-article:20220777pubmed:authorpubmed-author:GreinerJJlld:pubmed
pubmed-article:20220777pubmed:authorpubmed-author:DöhnerHHlld:pubmed
pubmed-article:20220777pubmed:authorpubmed-author:StilgenbauerS...lld:pubmed
pubmed-article:20220777pubmed:authorpubmed-author:KowalMMlld:pubmed
pubmed-article:20220777pubmed:authorpubmed-author:DmoszynskaAAlld:pubmed
pubmed-article:20220777pubmed:authorpubmed-author:RojewskiMMlld:pubmed
pubmed-article:20220777pubmed:authorpubmed-author:RolinskiJJlld:pubmed
pubmed-article:20220777pubmed:authorpubmed-author:GiannopoulouM...lld:pubmed
pubmed-article:20220777pubmed:authorpubmed-author:GostickEElld:pubmed
pubmed-article:20220777pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20220777pubmed:volume24lld:pubmed
pubmed-article:20220777pubmed:ownerNLMlld:pubmed
pubmed-article:20220777pubmed:authorsCompleteYlld:pubmed
pubmed-article:20220777pubmed:pagination798-805lld:pubmed
pubmed-article:20220777pubmed:meshHeadingpubmed-meshheading:20220777...lld:pubmed
pubmed-article:20220777pubmed:meshHeadingpubmed-meshheading:20220777...lld:pubmed
pubmed-article:20220777pubmed:meshHeadingpubmed-meshheading:20220777...lld:pubmed
pubmed-article:20220777pubmed:meshHeadingpubmed-meshheading:20220777...lld:pubmed
pubmed-article:20220777pubmed:meshHeadingpubmed-meshheading:20220777...lld:pubmed
pubmed-article:20220777pubmed:meshHeadingpubmed-meshheading:20220777...lld:pubmed
pubmed-article:20220777pubmed:meshHeadingpubmed-meshheading:20220777...lld:pubmed
pubmed-article:20220777pubmed:meshHeadingpubmed-meshheading:20220777...lld:pubmed
pubmed-article:20220777pubmed:meshHeadingpubmed-meshheading:20220777...lld:pubmed
pubmed-article:20220777pubmed:meshHeadingpubmed-meshheading:20220777...lld:pubmed
pubmed-article:20220777pubmed:meshHeadingpubmed-meshheading:20220777...lld:pubmed
pubmed-article:20220777pubmed:meshHeadingpubmed-meshheading:20220777...lld:pubmed
pubmed-article:20220777pubmed:meshHeadingpubmed-meshheading:20220777...lld:pubmed
pubmed-article:20220777pubmed:meshHeadingpubmed-meshheading:20220777...lld:pubmed
pubmed-article:20220777pubmed:meshHeadingpubmed-meshheading:20220777...lld:pubmed
pubmed-article:20220777pubmed:meshHeadingpubmed-meshheading:20220777...lld:pubmed
pubmed-article:20220777pubmed:meshHeadingpubmed-meshheading:20220777...lld:pubmed
pubmed-article:20220777pubmed:meshHeadingpubmed-meshheading:20220777...lld:pubmed
pubmed-article:20220777pubmed:meshHeadingpubmed-meshheading:20220777...lld:pubmed
pubmed-article:20220777pubmed:meshHeadingpubmed-meshheading:20220777...lld:pubmed
pubmed-article:20220777pubmed:meshHeadingpubmed-meshheading:20220777...lld:pubmed
pubmed-article:20220777pubmed:meshHeadingpubmed-meshheading:20220777...lld:pubmed
pubmed-article:20220777pubmed:meshHeadingpubmed-meshheading:20220777...lld:pubmed
pubmed-article:20220777pubmed:year2010lld:pubmed
pubmed-article:20220777pubmed:articleTitlePeptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia.lld:pubmed
pubmed-article:20220777pubmed:affiliationClinical Immunology Department, Medical University of Lublin, Lublin, Poland. giannop@tlen.pllld:pubmed
pubmed-article:20220777pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20220777pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:20220777pubmed:publicationTypeClinical Trial, Phase Illd:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:20220777lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:20220777lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:20220777lld:pubmed